{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:00:00Z","timestamp":1791201600036,"version":"4.2.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtos.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:23:14Z","timestamp":1790698994000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pipeline: Olympic medals and analyzing therapeutic trials in ocular surface disease"],"prefix":"10.1016","author":[{"given":"Gary D.","family":"Novack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2026.09.007_bib2","series-title":"Olympic Games medal count","year":"2026"},{"key":"10.1016\/j.jtos.2026.09.007_bib1","series-title":"International Olympics Committee - Mission statement","year":"2026"},{"key":"10.1016\/j.jtos.2026.09.007_bib3","article-title":"Who won the Winter olympics?","author":"Blatt","year":"2026","journal-title":"N Y Times"},{"key":"10.1016\/j.jtos.2026.09.007_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jtos.2025.02.001","article-title":"Pipeline: US FDA efficacy requirements for treatment of ocular surface disease: drugs vs. medical devices","volume":"36","author":"Kramm","year":"2025","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/10807683261422104","article-title":"Basis of approval for glaucoma drugs and devices: 2003-2025","volume":"42","author":"Kramm","year":"2026","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2026.09.007_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtos.2026.03.004","article-title":"Pipeline: design of therapeutic trials in Ocular Surface Disease","volume":"41","author":"Novack","year":"2026","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","article-title":"A randomized, vehicle-controlled, phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)","volume":"26","author":"Wirta","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtos.2023.07.002","article-title":"Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: a vehicle-controlled, randomized clinical trial","volume":"29","author":"Watson","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2024.11.008","article-title":"Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: a Phase 2, vehicle-controlled, randomized extension trial","volume":"35","author":"Downie","year":"2025","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jtos.2024.12.009","article-title":"AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: a vehicle-controlled, randomized, clinical trial","volume":"38","author":"Stapleton","year":"2025","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jtos.2026.04.006","article-title":"Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: a randomized, multicenter, double-masked, vehicle-controlled phase 3 trial","volume":"41","author":"Lu","year":"2026","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","article-title":"A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study","volume":"24","author":"Quiroz-Mercado","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2026.09.007_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jtos.2022.12.007","article-title":"A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease","volume":"28","author":"Tauber","year":"2023","journal-title":"Ocul Surf"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012426001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012426001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:34:35Z","timestamp":1791200075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012426001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"alternative-id":["S1542012426001242"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2026.09.007","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pipeline: Olympic medals and analyzing therapeutic trials in ocular surface disease","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}